Kimball Solutions experienced a mixed quarter, with revenue surpassing Wall Street expectations but adjusted earnings per share coming in significantly below consensus. Management attributed the revenue strength to robust organic sales growth, especially within the medical segment, as well as early contributions from the Helvoet acquisition. CEO Ric Phillips noted, “The organic growth was in line with expectations and driven by a high single-digit increase in medical sales.” However, margin pressure persisted due to higher component costs and ongoing investments in new facilities, which CFO Jana Croom indicated would weigh on near-term profitability.

Is now the time to buy KE? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Kimball Solutions’s Q3 earnings call

• Michael Crawford (B. Riley): asked about the drivers behind management’s increased optimism for Helvoet. CEO Ric Phillips highlighted stronger-than-expected talent integration and rising customer interest, noting daily opportunities for synergy.
• Michael Crawford (B. Riley): pressed on supply chain tightness and margin impacts. CFO Jana Croom clarified that memory and electronic components remain constrained, especially in automotive and industrial, but medical is less impacted due to more in-house assembly.
• Michael Crawford (B. Riley): inquired about inventory build. Croom attributed most of the increase to supporting resumed growth, particularly in medical, and not primarily to inflationary pressures.
• Michael Crawford (B. Riley): sought clarification on the tax rate spike. Croom explained the elevated rate was temporary, tied to cash repatriation for the Helvoet acquisition, and expects a return to lower rates for the remainder of the year.
• Brett Fishbin (KeyBanc Capital Markets): questioned how quickly the new Indianapolis medical facility will reach capacity. Phillips said customer tours and program wins are ramping, but full utilization will take time due to lengthy customer onboarding cycles.

Catalysts in upcoming quarters

Looking forward, the StockStory team will be watching (1) the pace of new program wins and production ramp-up at the Indianapolis medical CDMO facility, (2) evidence of successful synergy capture and revenue growth from the Helvoet integration, and (3) any improvement in gross margin as inflationary pressures and startup costs subside. Execution in portfolio diversification and ongoing demand in medical will also be key to monitoring progress.

Kimball Solutions currently trades at $20.54, down from $25.86 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High-quality stocks for all market conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.